Recent example of an ADC in cancerGSK got an antibody drug conjugate approved recently.
https://www.ema.europa.eu/en/news/first-antibody-drug-conjugate-multiple-myeloma-patients-limited-treatment-options This drug is similar to the concept of Theratech's drugs, replacing the SORT peptide with an antibody though (and to a different cancer antigen).
I thought the development timeline was interesting to look at.
The Ph1 started in 2014. They were reporting efficacy data from that trial by 2016
The Ph2 started in 2018 and we already now have approval.
I think there was speculation that you could get the first patients in Theratech's trial in 15 months. That might be true but a clear(ish) picture on efficacy may take a little longer but as you can see once you have that in the bag things can advance pretty swiftly.